Pulmonary function in long-term survivors of pediatric hematopoietic cell transplantation.

abstract：:Most publications report the adverse (negative) health issues in childhood cancer survivors. Presenting information to the newly diagnosed patient in a positive manner is advocated, while noting that recurrence is the most likely adverse event. Re-analysis of population-based studies on life-threatening toxicities fro...

journal_title：Pediatric blood & cancer

authors： Fryer C

更新日期：2011-12-15 00:00:00

abstract：BACKGROUND:Ewing tumors are the most frequent malignant tumors of the chest wall in children and young adults. Surgical management of these tumors can be challenging. Optimal local control remains controversial. The aim of this study was to analyze treatment, outcome, and surgical procedures in patients with thoracic t...

journal_title：Pediatric blood & cancer

authors： Seitz G,Urla C,Sparber-Sauer M,Schuck A,Vokuhl C,Blank B,Klingebiel T,Kazanowska B,Fuchs J,Koscielniak E

更新日期：2019-08-01 00:00:00

abstract：BACKGROUND:The level of minimal residual disease (MRD) prior to allogeneic hematopoietic stem cell transplantation (HSCT) has been shown to be an independent prognostic factor for outcome of pediatric patients with high-risk acute lymphoblastic leukemia (ALL). Retrospective studies which used (semi-) quantitation of cl...

journal_title：Pediatric blood & cancer

authors： Sramkova L,Muzikova K,Fronkova E,Krejci O,Sedlacek P,Formankova R,Mejstrikova E,Stary J,Trka J

更新日期：2007-01-01 00:00:00

abstract：BACKGROUND:Robatumumab (19D12; MK-7454 otherwise known as SCH717454) is a fully human antibody that binds to and inhibits insulin-like growth factor receptor-1 (IGF-1R). This multiinstitutional study (P04720) determined the safety and clinical efficacy of robatumumab in three separate patient groups with resectable ost...

journal_title：Pediatric blood & cancer

authors： Anderson PM,Bielack SS,Gorlick RG,Skubitz K,Daw NC,Herzog CE,Monge OR,Lassaletta A,Boldrini E,Pápai Z,Rubino J,Pathiraja K,Hille DA,Ayers M,Yao SL,Nebozhyn M,Lu B,Mauro D

更新日期：2016-10-01 00:00:00

abstract：:High dose acetaminophen (HDAC) with N-acetylcysteine (NAC) has been effective in adults with advanced malignancies. We report HDAC with NAC in a child with progressive hepatoblastoma, confirmed at biopsy of an unresectable hepatic mass. Alpha-fetoprotein (AFP) increased despite four courses of doxorubicin and one cour...

journal_title：Pediatric blood & cancer

authors： Kobrinsky NL,Sjolander DE,Goldenberg JA,Ortmeier TC

更新日期：2005-08-01 00:00:00

abstract：BACKGROUND:Wilms tumor is the most common pediatric renal malignancy, but the parameters that are important to its invasion capacity are poorly understood. The aim of this study was to identify new proteins associated with the invasion capacity of Wilms tumor. PROCEDURE:Gene expression profiles for 15 primary Wilms tu...

journal_title：Pediatric blood & cancer

authors： Chetcuti A,Aktas S,Mackie N,Ulger C,Toruner G,Alkan M,Catchpoole D

更新日期：2011-12-01 00:00:00

abstract：BACKGROUND:Osteopenia has been reported in children surviving acute lymphoblastic leukemia and brain tumors, apparently as a consequence of therapy. It has been suggested that cranial irradiation may play a role in the development of this complication. In order to explore that possibility, we examined survivors of brai...

journal_title：Pediatric blood & cancer

authors： Odame I,Duckworth J,Talsma D,Beaumont L,Furlong W,Webber C,Barr R

更新日期：2006-03-01 00:00:00

abstract：BACKGROUND:Radiation therapy (RT)-induced effects in children treated for low grade glioma (LGG) can result in worsening of neurologic symptoms and clinical and radiographic deterioration. Treatment for radiation-induced tumor enlargement is based on symptom control and usually involves steroids. PROCEDURE:We conducte...

journal_title：Pediatric blood & cancer

authors： Foster KA,Ares WJ,Pollack IF,Jakacki RI

更新日期：2015-02-01 00:00:00

abstract：BACKGROUND:Children and adolescents with Non-Hodgkin lymphoma (NHL) and mature B-cell leukemia (B-ALL) have an excellent prognosis with contemporary chemotherapy stratified according to the histologic subtype and clinical stage of disease. However, a small subset of patients does not respond to front-line therapy or su...

journal_title：Pediatric blood & cancer

authors： Attarbaschi A,Dworzak M,Steiner M,Urban C,Fink FM,Reiter A,Gadner H,Mann G

更新日期：2005-01-01 00:00:00

abstract：:The commonly accepted definition of Fanconi anemia (FA) relying on DNA repair deficiency is submitted to a critical review starting from the early reports pointing to mitomycin C bioactivation and to the toxicity mechanisms of diepoxybutane and a group of nitrogen mustards causing DNA crosslinks in FA cells. A critica...

journal_title：Pediatric blood & cancer

authors： Pagano G,d'Ischia M,Pallardó FV

更新日期：2015-07-01 00:00:00

abstract：BACKGROUND:Previous studies of children with homozygous sickle cell anemia (SCA) show impaired growth and maturation. The correlation of this suboptimal growth with metabolic and hematological factors during puberty is poorly understood. PROCEDURE:We studied a group of pre-adolescent children with SCA (19 males, 14 fe...

journal_title：Pediatric blood & cancer

authors： Rhodes M,Akohoue SA,Shankar SM,Fleming I,Qi An A,Yu C,Acra S,Buchowski MS

更新日期：2009-10-01 00:00:00

abstract：:Essential thrombocythemia is a rare myleoproliferative disorder in pediatrics. This myleoproliferative disorder is characterized by excessive proliferation of megakaryocytes and sustained elevation of platelet count. Reactive thrombocytosis is a more common cause of elevated platelet counts among children. We describe...

journal_title：Pediatric blood & cancer

authors： Robins EB,Niazi M

更新日期：2008-04-01 00:00:00

abstract：BACKGROUND:Epoetin alfa (EPO, PROCRIT) pharmacokinetics and pharmacodynamics were evaluated in children with malignant solid tumors receiving chemotherapy. PROCEDURE:Children initially received IV EPO 600 IU/kg (max dose 40,000 IU) or placebo once weekly for 16 weeks. Dose was increased to 900 IU/kg (max dose 60,000 I...

journal_title：Pediatric blood & cancer

authors： Freeman BB 3rd,Hinds P,Iacono LC,Razzouk BI,Burghen E,Stewart CF

更新日期：2006-10-15 00:00:00

abstract：BACKGROUND:Neuroblastoma (NB) is cytogenetically characterized by a number of non-random events. However, knowledge is limited concerning the timing of occurrence and inter-action of many of these events. METHODS:Karyotypic patterns were obtained from a study group of 49 NB tumors that had been analyzed by conventiona...

journal_title：Pediatric blood & cancer

authors： Betts DR,Cohen N,Leibundgut KE,Kühne T,Caflisch U,Greiner J,Traktenbrot L,Niggli FK

更新日期：2005-02-01 00:00:00

abstract：:Myasthenia gravis is among the rare complications after allogeneic hematopoietic stem cell transplantation and is usually associated with chronic GVHD. Herein, we report a 2-year and 10 months of age female with Griscelli syndrome, who developed severe myasthenia gravis at post-transplant +22nd month and required resp...

journal_title：Pediatric blood & cancer

authors： Unal S,Sag E,Kuskonmaz B,Kesici S,Bayrakci B,Ayvaz DC,Tezcan I,Yalnızoglu D,Uckan D

更新日期：2014-05-01 00:00:00

abstract：:Chronic hypoxemia is a common manifestation among patients with sickle cell anemia (SCA) who develop chronic lung disease. We report the beneficial effect of hydroxyurea on chronic hypoxemia in three pediatric patients with SCA and recurrent episodes of acute chest syndrome (ACS). All three patients improved rapidly a...

journal_title：Pediatric blood & cancer

authors： Singh SA,Koumbourlis AC,Aygun B

更新日期：2008-06-01 00:00:00

abstract：BACKGROUND:The aim of the study was to investigate factors affecting response to everolimus, a mammalian-target-of-rapamycin (mTOR) inhibitor, of subependymal giant cell astrocytomas (SEGA) in patients with tuberous sclerosis complex (TSC). METHODS:The study group consisted of 15 children with a diagnosis of TSC-relat...

journal_title：Pediatric blood & cancer

authors： Trelinska J,Dachowska I,Kotulska K,Baranska D,Fendler W,Jozwiak S,Mlynarski W

更新日期：2015-04-01 00:00:00

abstract：BACKGROUND:A pediatric Phase I trial was performed to determine the maximum-tolerated dose, dose-limiting toxicities (DLTs), and pharmacokinetics (PK) of vorinostat and bortezomib, in patients with solid tumors. PROCEDURE:Oral vorinostat was administered on days 1-5 and 8-12 of a 21-day cycle (starting dose 180 mg/m(2...

journal_title：Pediatric blood & cancer

authors： Muscal JA,Thompson PA,Horton TM,Ingle AM,Ahern CH,McGovern RM,Reid JM,Ames MM,Espinoza-Delgado I,Weigel BJ,Blaney SM

更新日期：2013-03-01 00:00:00

abstract：BACKGROUND:The purpose of our study was to assess long-term cause-specific mortality of 5-year childhood cancer survivors. PROCEDURE:The study population consisted of 1,378 patients who had been treated for childhood cancer in The Netherlands between 1966 and 1996 and survived at least 5 years; follow-up was complete ...

journal_title：Pediatric blood & cancer

authors： Cardous-Ubbink MC,Heinen RC,Langeveld NE,Bakker PJ,Voûte PA,Caron HN,van Leeuwen FE

更新日期：2004-06-01 00:00:00

abstract：:We report three cases of hemophagocytic lymphohistiocytosis (HLH) in infants within the first 6 weeks of life. Diagnosis of HLH was made early after symptoms started. All three cases were successfully treated with dexamethasone and none relapsed, indicating that not all cases of HLH in very young infants are familial....

journal_title：Pediatric blood & cancer

authors： Tanoshima R,Takahashi H,Hokosaki T,Yamaguchi K,Goto S,Kai S

更新日期：2009-01-01 00:00:00

abstract：:Pediatric renal cell carcinoma (RCC) is a rare cancer that can be associated with inherited diseases including tuberous sclerosis complex (TSC) caused by germline mutations in TSC1 or TSC2. Somatic mutations in TSC1 and TSC2 have also been reported in adult RCC, which predict response to mTOR inhibitors. Here, we pres...

journal_title：Pediatric blood & cancer

authors： Potter SL,Venkatramani R,Wenderfer S,Graham BH,Vasudevan SA,Sher A,Wu H,Wheeler DA,Yang Y,Eng CM,Gibbs RA,Roy A,Plon SE,Parsons DW

更新日期：2017-05-01 00:00:00

abstract：:Neuroblastoma is the most common extracranial solid tumor of childhood, and the outcomes for children with high-risk and relapsed disease remain poor. However, new international strategies for risk stratification and for treatment based on novel tumor targets and including immunotherapy are being employed in attempts ...

journal_title：Pediatric blood & cancer

authors： Zage PE,Louis CU,Cohn SL

更新日期：2012-07-01 00:00:00

abstract：:Evidence of the laboratory benefits of hydroxyurea and its clinical efficacy in reducing acute vaso-occlusive events in adults and children with sickle cell anemia has accumulated for more than 15 years. A definitive clinical trial showing that hydroxyurea can also prevent organ damage might support widespread use of ...

journal_title：Pediatric blood & cancer

authors： Thompson BW,Miller ST,Rogers ZR,Rees RC,Ware RE,Waclawiw MA,Iyer RV,Casella JF,Luchtman-Jones L,Rana S,Thornburg CD,Kalpatthi RV,Barredo JC,Brown RC,Sarnaik S,Howard TH,Luck L,Wang WC

更新日期：2010-02-01 00:00:00

abstract：:A 4(3/4)-year-old male with Down syndrome (DS) presented with unsteady gait and fatigue. Neuroimaging revealed a cerebellar mass with concomitant obstructive hydrocephalus and additional metastatic lesions. He was successfully treated and is still in complete remission 5 years from diagnosis. The present case illustra...

journal_title：Pediatric blood & cancer

authors： Benesch M,Moser A,Sovinz P,Lackner H,Schwinger W,Eder H,Urban C

更新日期：2009-12-01 00:00:00

abstract：:Aplastic anemia (AA) is an immune-mediated disease. Although most patients are responsive to immunosuppressive therapy (IST) with a combination of anti-thymocyte globulin (ATG) and cyclosporine (CsA), some patients relapse or are refractory to IST. Sirolimus (rapamysin) inhibits the serine-threonine kinase mammalian t...

journal_title：Pediatric blood & cancer

authors： He G,Zhang X,Wu D,Sun A,Wang X

更新日期：2011-07-01 00:00:00

abstract：:Although awareness of implicit bias and its influence on providers and patients is increasing, the effects of implicit bias on the field of pediatric hematology-oncology are less clear. This Special Report reviews the literature on implicit bias in pediatrics and medical oncology and further provides case examples and...

journal_title：Pediatric blood & cancer

authors： Tsai JW,Kesselheim JC

更新日期：2020-05-01 00:00:00

abstract：:Efficacy of therapeutic strategies relative to patient- and family-centered outcomes in pediatric oncology must be assessed. We sought to identify outcomes important to children with acute myeloid leukemia and their families related to inpatient versus at-home management of neutropenia. We conducted qualitative interv...

journal_title：Pediatric blood & cancer

authors： Szymczak JE,Getz KD,Madding R,Fisher B,Raetz E,Hijiya N,Gramatges MM,Henry M,Mian A,Arnold SD,Aftandilian C,Collier AB,Aplenc R

更新日期：2018-04-01 00:00:00

abstract：:The provision of tele-practice symptom management is often without the provision of evidence-based guidelines. Under the auspices of the Pediatric Oncology Group of Ontario, a nursing task force was established to appraise the evidence and develop guidelines. Promising new efforts to enhance symptom management through...

journal_title：Pediatric blood & cancer

authors： Tsimicalis A,De Courcy MJ,Di Monte B,Armstrong C,Bambury P,Constantin J,Dagelman B,Eves M,Jansen P,Honeyford L,Stregger D,Pediatric Oncology Group of Ontario.

更新日期：2011-10-01 00:00:00

abstract：BACKGROUND:Atypical teratoid/rhabdoid tumor (AT/RT) is a highly malignant embryonal brain tumor that occurs mainly in early childhood. Although most of the tumors are characterized by inactivating mutations of the tumor suppressor gene, SMARCB1, the biological basis of its tumorigenesis and aggressiveness is still unkn...

journal_title：Pediatric blood & cancer

authors： Suzuki M,Kondo A,Ogino I,Arai H,Tomita T,Sredni ST

更新日期：2017-07-01 00:00:00

abstract：BACKGROUND:The high cost, coupled with the need for continuous infusion, renders Desferrioxamine (DFO), a non-feasible option for iron-chelation in a large majority of patients with β-thalassemia major in developing countries. Monotherapy with deferiprone (DFP) or deferasirox (DFX) may not always attain optimal control...

journal_title：Pediatric blood & cancer

authors： Totadri S,Bansal D,Bhatia P,Attri SV,Trehan A,Marwaha RK

更新日期：2015-09-01 00:00:00